Physiotherapy practice in IRVING · TX · US. Official registry identity, filed financial evidence and a public indicative value curve on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsThe historical value curve is public. Create a free account for the indicative five-year outlook, the assumptions behind it, and concrete actions to increase value.
Free account · private workspace
Each step adds evidence that narrows the range. Public filings are a starting point. Connected accounts, owner context and method review make the valuation more useful for real decisions.
Continue privately and connect your accounting data to make the graph more accurate.
Continue as ownerTrack the buying status below. If the owner opens a process, you can request a conversation and review the details before making an offer.
View buying statusYou have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for Caris Life Sciences, Inc. combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Caris Life Sciences, Inc., a physiotherapy practice, is registered at an address in IRVING, TX, the United States.
Caris Life Sciences, Inc. is listed in US Securities and Exchange Commission (SEC EDGAR) under registry number 0002019410. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 86.90 band file annual accounts with SEC EDGAR.
The most recently filed revenue (2025) stands at €812,033,000. EBITDA for 2025 comes in at €67,728,000.
A public indicative value curve is available for Caris Life Sciences, Inc., based on filed company accounts. A free account unlocks the five-year outlook and concrete actions to increase value.
The most recent annual filing covers 2025 (period end 2025-12-31).
The data on this page is a public, point-in-time projection of Caris Life Sciences, Inc.'s regulator-filed footprint, built to support indicative valuation bands, sellability context, and acquisition research.
Public regulator-filed figures across 4 years.
Caris Life Sciences, Inc. is registered under NACE 86.90: SEC SIC 1987 8071 mapped to NACE Rev. 2 86.90. That places the business within the American cluster for this activity.
According to the company registry, Caris Life Sciences, Inc. is based in IRVING, TX, US.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for Caris Life Sciences, Inc. may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
| 202331 Dec 2023 | €306,128,000 | -€270,550,000 | - | -€2,144,950,000 | Open PDF |
| 202231 Dec 2022 | - | - | - | -€1,702,113,000 | Open PDF |
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-12-31), publicly available via US Securities and Exchange Commission (SEC EDGAR).
